Logo-bi
Original Research
Mohammad Mostafa Pourseif, Gholamali Moghaddam*, Hossein Daghighkia, Ahmad Nematollahi, Yadollah Omidi* ORCID
Bioimpacts. 2018;8(1): 39-52. doi: 10.15171/bi.2018.06
PMCID: PMC5915707     PMID: 29713601     Scopus ID: 85044310762    
Review
Sepideh Parvizpour, Jafar Razmara, Yadollah Omidi* ORCID
Bioimpacts. 2018;8(3): 223-235. doi: 10.15171/bi.2018.25
PMCID: PMC6128970     PMID: 30211082     Scopus ID: 85050689925    
Original Research
Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi* ORCID
Bioimpacts. 2019;9(1): 45-56. doi: 10.15171/bi.2019.06
PMCID: PMC6378095     PMID: 30788259     Scopus ID: 85060470196    
Using immunoinformatic tools, a multi-epitope peptide vaccine (consisting of CD8+cytotoxic T lymphocytes epitopes, helper epitopes and adjuvant) was designed to combat the triple-negative breast cancer. The vaccine showed acceptable immunogenicity and potential to stimulate both cellular and humoral immune responses.
Original Research
Mohammad Mostafa Pourseif, Mitra Yousefpour*, Mohammad Aminianfar, Gholamali Moghaddam, Ahmad Nematollahi ORCID
Bioimpacts. 2019;9(3): 131-144. doi: 10.15171/bi.2019.18
PMCID: PMC6726745     PMID: 31508329     Scopus ID: 85071191509    
The minigene vaccine construct is designed based on the B and T cell epitopes of E. granulosus enolase protein, and ligands for TLR-2 and TLR-4. The minigene vaccine showed stable properties for proper binding with the Toll-like receptors.
Original Research COVID-19
Mohammad Mostafa Pourseif ORCID, Sepideh Parvizpour, Behzad Jafari, Jaber Dehghani ORCID, Behrouz Naghili, Yadollah Omidi* ORCID
BioImpacts. 2021;11(1): 65-84. doi: 10.34172/bi.2021.11
PMCID: PMC7803919     PMID: 33469510     Scopus ID: 85099197264    
Immunodominant T-cell epitopes of SARS-CoV-2 spike protein with the highest population coverage were predicted by analyzing peptide binders and consensus rank (CR) score. Multi-method B-cell epitope prediction approach was used to find B-cell immunodominant regions of spike protein. Upon the high immune-potent regions of the antigen(s), self-amplifying mRNA and peptide-based vaccines were designed.

Original Research
Ysrafil Ysrafil* ORCID, Zulfiayu Sapiun ORCID, Indwiani Astuti ORCID, Mohammad Anas Anasiru, Nangsih Sulastri Slamet ORCID, Hartati Hartati ORCID, Fadli Husain, Sukmawati Ahmad Damiti ORCID
BioImpacts. 2022;12(4): 359-370. doi: 10.34172/bi.2022.23769
PMCID: PMC9376164     PMID: 35975206     Scopus ID: 85138027836    
The two designed and constructed multiepitope vaccine have good characteristics and may have the potential to activate humoral and cellular immune responses against SARS-CoV-2. Further research is worth considering to confirm the findings of this study.
Original Article
Maryam Rezaei ORCID, Mehri Habibi, Parasoo Ehsani, Mohammad Reza Asadi Karam*, Saeid Bouzari* ORCID
Bioimpacts. 2024;14(1): 27513. doi: 10.34172/bi.2023.27513
PMCID: PMC10844585     PMID: 38327629    
Original Article
Sari Eka Pratiwi* ORCID, Ysrafil Ysrafil ORCID, Mardhia Mardhia ORCID, Mahyarudin Mahyarudin ORCID, Muhammad Inam Ilmiawan, Heru Fajar Trianto, Delima Fajar Liana, Yuri Amia
Bioimpacts. 2024;14(5): 27846. doi: 10.34172/bi.2024.27846
PMCID: PMC11406424     PMID: 39296802    


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge